| Literature DB >> 36171339 |
Rana I Mahmood1, Afraa Ali Kadhim2, Sumayah Ibraheem3, Salim Albukhaty4,5, Harraa S Mohammed-Salih6, Ruaa H Abbas7, Majid S Jabir8, Mustafa K A Mohammed9, Uday M Nayef10, Faizah A AlMalki11, Ghassan M Sulaiman10, Hassan Al-Karagoly12.
Abstract
This study investigated for the first time a simple bio-synthesis approach for the synthesis of copper oxide nanoparticles (CuO NPs) using Annona muricata L (A. muricata) plant extract to test their anti-cancer effects. The presence of CuONPs was confirmed by UV-visible spectroscopy, Scanning electron microscope (SEM), and Transmission electron microscope (TEM). The antiproliferative properties of the synthesized nanoparticles were evaluated against (AMJ-13), (MCF-7) breast cancer cell lines, and the human breast epithelial cell line (HBL-100) as healthy cells. This study indicates that CuONPs reduced cell proliferation for AMJ-13 and MCF-7. HBL-100 cells were not significantly inhibited for several concentration levels or test periods. The outcomes suggest that the prepared copper oxide nanoparticles acted against the growth of specific cell lines observed in breast cancer. It was observed that cancer cells had minor colony creation after 24 h sustained CuONPs exposure using (IC50) concentration for AMJ-13 was (17.04 µg mL-1). While for MCF-7 cells was (18.92 µg mL-1). It indicates the uptake of CuONPs by cancer cells, triggering apoptosis. Moreover, treatment with CuONPs enhanced Lactate dehydrogenase (LDH) production, probably caused by cell membrane damage, creating leaks comprising cellular substances like lactate dehydrogenase. Hence, research results suggested that the synthesized CuONPs precipitated anti-proliferative effects by triggering cell death through apoptosis.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36171339 PMCID: PMC9519583 DOI: 10.1038/s41598-022-20360-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1UV-spectroscopy of CuONPs.
Figure 2Structural and Morphological Properties of CuO NPs. (A) SEM image. (B) Diameter (nm) of CuONPs ranged between 33.24 ± 6.49 nm. (C) TEM image.
Figure 3CuO NPs increase the release of lactate dehydrogenase (LDH) production. (A) control untreated cells. (B) Cells treated with 25 µg cells mL−1 of CuO NPs. (C) Cells treated with 50 µg cells mL−1 of CuO NPs. (D) Cells treated with 100 µg cells mL−1 of CuO NPs. 1% Triton-x was employed for positive control reference (E). LDH release was measured at 490 nm. Results are represented as mean ± SD.
Figure 4The Antiproliferative activity of CuO NPs against cancer cell lines. Triplicate samples of AMJ-13, MCF-7, and HBL-100 cells at a concentration of 1 × 104 cells mL−1 were seeded. CuO NPs were added to these samples and incubation periods for 72 h. Cells were stained with MTT. The 492 nm wavelength was selected to assess absorbance.
Figure 5CuONPs inhibit the Colony-forming of MCF-7 and AMJ-13. A 24-h CuONPs treatment was provided at IC50 concentration, followed by crystal violet staining for 20 min.
Figure 6Apoptosis markers in cancer cells after treatment with CuO NPs. (A) Apoptotic indicators for AMJ-13, MCF-7, and HBL-100 cells exposed to CuONPs at IC50 concentrations for 24 h and stained for 2 min using AO/EtBr. Unexposed cells have an intact structure. Nevertheless, CuONPs exposure correlated with apoptotic aspects indicated using red stains. Scale bar 10 µm. (B) Cells cycle phase. Sub-G1 phase concerning MCF-7 and AMJ-13 cells’ flow cytometry.
Figure 7CuONPs up-regulated Caspase-3 and Caspase-9 expresion. Flow cytometry was used to analyse fluorescence histograms of immunolabeled caspase-3 and caspase-9.